-
Voriconazole tablets, a subsidiary of Jingfeng Pharmaceuticals, obtained the drug registration certificate
Time of Update: 2021-11-05
In addition, voriconazole also has a bactericidal effect against other pathogenic fungi in vitro, including bacteria that are less sensitive to current antifungal drugs, such as Actinomyces and Fusarium .
-
The national drug counter is here!
Time of Update: 2021-11-05
One week after pharmacies set up the "National Central Procurement Drug Sales Counter", the number of drugs sold increased by 46% on average, and the highest increase was 80% .
-
Pfizer/BioNTech mRNA vaccine to prevent influenza enters the clinic
Time of Update: 2021-11-05
The flexibility of mRNA technology and its rapid production may allow better virus strain matching, stronger supply reliability, and improved influenza vaccine effectiveness .
In addition, in the case of pandemic influenza, mRNA technology can allow rapid and large-scale production of effective vaccines .
-
China's first new crown "special effect medicine" screen?
Time of Update: 2021-11-05
The health and hygiene zone established for the first time by the China International Trade in Services, where intravenous injection of COVID-19 human immunoglobulin (pH4), referred to as "new crown special immunity" and recombinant fully human anti-new crown virus monoclonal antibody injection-two This special medicine and the second-generation vaccine against mutant strains such as Delta are the world's first releases .
-
Huabei Pharmaceutical's Amoxicillin Sodium and Clavulanate Potassium for Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-11-05
On August 26, North China Pharmaceutical issued an announcement stating that it had recently received the "Notice of Approval of Supplementary Drug Application" for Amoxicillin Sodium and Clavulanate Potassium for Injection (0.
To reduce the chance of drug resistance .
-
Fu'an Pharmaceutical obtained drug registration certificate for Esomeprazole Sodium for Injection
Time of Update: 2021-11-05
On September 16, Fu'an Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Chu Pharmaceutical, had recently received a drug registration certificate for Esomeprazole Sodium for Injection approved and issued by the National Medical Products Administration .
-
It's time for pharmacies to transform
Time of Update: 2021-11-04
New pharmaceutical retail, relying on the Internet information platform, implements online orders and offline distribution .
The reason why a large number of physical stores will be transformed or closed is because they have not adapted to the rise of new retail models .
-
Clinical trial of AstraZeneca anticancer drug AZD5991 suspended due to cardiac safety risks
Time of Update: 2021-11-04
gov), AstraZeneca has suspended a phase 1 clinical trial of its experimental blood cancer drug MCL-1 inhibitor AZD5991 .
The trial aims to evaluate the efficacy and safety of AZD5991 as a monotherapy or in combination with AbbVie/Roche's listed blood cancer drug Venclexta (venetoclax) in the treatment of relapsed or refractory hematological malignancies .
-
By 2025, the scale of the biomedical industry in Tianjin Binhai New Area will reach 100 billion yuan
Time of Update: 2021-11-04
It is reported that during the "14th Five-Year Plan" period, the biomedical industry in Binhai New Area will promote the construction of the biological manufacturing valley and the characteristic "cell valley" of Beijing-Tianjin-Hebei, focusing on key areas such as synthetic biology, vaccines, cell and gene therapy, and creating biological medicine and chemistry.
-
Localities are vigorously promoting the development of Chinese medicine, internationalization is becoming a major trend
Time of Update: 2021-11-04
In recent years, in order to vigorously promote the inheritance, innovation and development of Chinese medicine in China, the state has issued a series of favorable measures .
-
Gansu Provincial Human Resources Examination Center issued a notice: this year's licensed pharmacist exam will be cancelled
Time of Update: 2021-11-04
According to the relevant arrangements of the "Notice of the General Office of the Ministry of Human Resources and Social Security on the 2021 Professional and Technical Personnel Vocational Qualification Examination Work Plan and Related Matters", the 2021 licensed pharmacist vocational qualification examination will be held on October 23 and 24 .
-
From October 20th, the fifth batch of centralized procurement drugs in a batch of provinces will be concentrated
Time of Update: 2021-11-04
Shaanxi The Shaanxi Provincial Medical Insurance Bureau issued a notice on September 10, which clearly stated that the results of the fifth batch of nationally organized drug centralized procurement will be officially implemented in Shaanxi Province from 0:00 on October 20, 2021 .
-
A breakthrough in Yangtze River's proprietary Chinese medicines!
Time of Update: 2021-11-04
Figure 1: New drugs declared by Yangtze River since 2021Source: CDE official websiteFigure 2: Clinical progress of new drugsSource: China Drug Clinical Trial Publicity Library of MeinenetSince the beginning of this year, Yangtze River has applied for clinical application of 3 new drugs: the indication is analgesic chemical medicine Class 1 new drug YR-1702 injection and the indication is seasonal allergic rhinitis Chinese medicine Class 2.
-
How to Promote the High-quality Development of Public Hospitals Jilin Province Issues Implementation Opinions
Time of Update: 2021-11-04
，《》（《》）。 《》、、、、、、。，《》， 5 ，，，，、、。 《》： 〔2021〕43 （），，、（），（），、： 《》（〔2021〕18），，，、，，。 、 ，、、、，，，，，，5，，，，、、。 、 （）。3，、，，，，，、。，、、、、，“”。 (2) Strengthen the construction of public hospitals in prefectures an
-
The tens of billions of diabetes drug market will usher in strong competitors
Time of Update: 2021-11-04
According to reports, Microchip's new class 1 diabetes drug "siglita sodium" has been approved recently and is expected to be approved for marketing in the near future .
-
New developments in epilepsy drugs: eslicarbazepine's first imitation approved soon
Time of Update: 2021-11-04
In China, the original eslicarbazepine acetate has not been approved for marketing, but the drug has been included in the "Second Batch of Encouraging Generic Drugs List" published on the National Health Commission website in March 2021 .
-
Zai Lab and Entasis Therapeutics announce positive key results of SUL-DUR Phase 3 clinical study ATTACK
Time of Update: 2021-11-04
In patients with carbapenem-resistant Acinetobacter infection (CRABC m-MITT [1] population of the study in Part A), SUL-DUR treatment reached the main study endpoint of 28-day all-cause mortality, indicating that there is more Compared with colistin, SUL-DUR treatment has statistically significant non-inferiority .
-
Approval of innovative drugs continues to accelerate, with more than 25 domestically-made new drugs on the market
Time of Update: 2021-11-04
Another example is Huahai Pharmaceutical's research and development investment accounted for more than 10% of revenue in recent years.
Data show that from 2016 to 2019, the market size of China's innovative drug industry increased from US$113.
-
Yasheng Pharmaceutical's new and potent EED inhibitor research results are published on JMC
Time of Update: 2021-11-04
The leading journal in the field, the Journal of Medicinal Chemistry, published an article revealing the potential of the potent oral embryonic ectodermal development protein (EED) inhibitor EEDi-5273 (ie APG-5918), which is expected to regulate tumor epigenetics and tumor microenvironment Overcome tumor drug resistance and achieve complete and lasting tumor regression .
-
In the context of AI, drug R&D innovation is accelerating
Time of Update: 2021-11-04
Some time ago, Huawei also released the "Huawei Cloud Pangu" drug molecular model, which is a new breakthrough for Huawei to enter the field of AI-assisted drug research and development .
